Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topotecan disposition in an anephric child.

Lisa C Iacono1, Denise Adams, Alan C Homans

  • 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

Journal of Pediatric Hematology/Oncology
|September 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study.

Clinical pharmacokinetics·2026
Same author

Health-Related Quality of Life and Symptom Severity Among Patients With PIK3CA-Related Overgrowth Spectrum: A Mixed-Methods Study to Understand Real-World Experience With Alpelisib Treatment.

Pediatric blood & cancer·2026
Same author

Hybrid Systems Modeling of Donor T-Cell Responses and Graft-Versus-Host-Disease After Posttransplantation Cyclophosphamide Administration.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.

Neuro-oncology pediatrics·2026
Same author

Somatic Genetic Testing Provides Diagnosis of Verrucous Venous Malformation in an Individual with Discrepant Radiology, Pathology, and Clinical Findings.

Journal of vascular anomalies·2026
Same author

Impact of anticoagulation on quality of life in patients with slow-flow vascular malformations.

Blood vessels, thrombosis & hemostasis·2025
Same journal

Assessment of Immunization Status Following Non-HSCT Chemotherapy-treated Pediatric Leukemia Survivors.

Journal of pediatric hematology/oncology·2026
Same journal

Frequent Use of Hematologic Testing in Children Admitted for Nonaccidental Trauma.

Journal of pediatric hematology/oncology·2026
Same journal

Unresponsive Systemic Mastocytosis in a Young AML With RUNX1::RUNX1T1 Fusion With Rare KIT c.1255_1257delGAC Mutation: A Clinical Deadlock.

Journal of pediatric hematology/oncology·2026
Same journal

Local Control and Survival Outcomes in Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: The Mayo Clinic Experience.

Journal of pediatric hematology/oncology·2026
Same journal

Diagnostic Pitfalls in Pediatric Acute Promyelocytic Leukemia: All-trans Retinoic Acid-Associated Hypercalcemia Mimicking Fungal Meningitis and the Risks of Azole Coadministration.

Journal of pediatric hematology/oncology·2026
Same journal

Unmanipulated Haploidentical Stem Cell Transplantation Outcome in a Pediatric Patient With CD27 Deficiency and EBV-Induced Diffuse Large B-Cell Lymphoma With Primary CNS Involvement.

Journal of pediatric hematology/oncology·2026
See all related articles

Topotecan disposition was studied in an anephric child with Wilms tumor undergoing hemodialysis. The chemotherapy drug's clearance was minimally affected by hemodialysis, showing similar levels to patients without renal failure.

Area of Science:

  • Pharmacokinetics
  • Pediatric Oncology
  • Nephrology

Background:

  • Limited data exist on topotecan pharmacokinetics in renal insufficiency.
  • No data were available for anephric patients, particularly children.

Observation:

  • A single pediatric patient with Wilms tumor and no renal function was studied.
  • The patient received combination therapy with topotecan and cyclophosphamide.
  • Hemodialysis was administered on days 2 and 4 of each 5-day topotecan cycle.

Findings:

  • Topotecan lactone clearance was 15.5 L/h/m off hemodialysis and 18.7 L/h/m on hemodialysis.
  • Topotecan clearance was minimally impacted by hemodialysis.
  • The observed clearance was comparable to that in pediatric patients with normal renal function.

Related Experiment Videos

Implications:

  • Topotecan may be safely administered to anephric pediatric patients undergoing hemodialysis.
  • These findings support further investigation into topotecan dosing in pediatric patients with end-stage renal disease.
  • Understanding topotecan disposition is crucial for optimizing chemotherapy in vulnerable pediatric populations.